BooksTestimonialsInterviewsLibraryArticles 

Library

Library of Scientific Studies Funded and Published by others and Hepatitis C articles from other sources..

Naringenin inhibits production of hepatitis C virus

Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism.
Goldwasser J
, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML, Nahmias Y.

Source

Center for Engineering in Medicine, Shriners Burns Hospital, Boston, MA, USA; Harvard-MIT Division of Health Science and Technology, Cambridge, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract
BACKGROUND & AIMS:

Hepatitis C virus (HCV) infection affects 3% of the world population and is the leading cause of chronic liver disease worldwide. Current standard of care is effective in only 50% of the patients, poorly tolerated, and associated with significant side effects and viral resistance. Recently, our group and others demonstrated that the HCV lifecycle is critically dependent on host lipid metabolism and that its production is metabolically modulated.

METHODS:

The JFH1/Huh7.5.1 full lifecycle model of HCV was used to study the antiviral effects of naringenin on viral replication, assembly, and production. Activation of PPAR? was elucidated using GAL4-PPAR? fusion reporters, PPRE reporters, qRT-PCR, and metabolic studies. Metabolic results were confirmed in primary human hepatocytes

Rawesome Foods Target of Multi Agency Raid

WHO: Hospital Stay Riskier Than Flying

Millions of people die each year from medical errors and infections linked to healthcare and going into hospital is far riskier than flying, the World Health Organization said on Thursday.

"If you were admitted to hospital tomorrow in any country ... your chances of being subjected to an error in your care would be something like one in 10. Your chances of dying due to an error in healthcare would be 1 in 300," Liam Donaldson, the WHO's newly appointed envoy for patient safety, told a news briefing.

FDA's scheme to outlaw all nutritional supplements created after 1994 would destroy millions of jobs and devastate economy

Yesterday we reported on the FDA's new scheme for outlawing nearly all nutritional supplements formulated after October, 1994 (http://www.naturalnews.com/032912_F...). That was just the beginning of this story, because a detailed analysis of the proposed new regulation reveals extremely disturbing revelations that would absolutely gut the nutritional products industry if these regulations are put into practice.

FDA’s New Sneak Attack on Supplements

Just before the July 4 holiday weekend, hoping to limit media attention, the FDA dropped a bomb on dietary supplements. Don’t let them get away with it! A new Action Alert.

On July 1, the US Food and Drug Administration issued draft guidance for complying with the New Dietary Ingredient (NDI) notification protocols contained in the Dietary Supplement Health and Education Act (DSHEA). Ever since DSHEA was enacted in 1994, supplement manufacturers have had very little guidance on what counts as an NDI and when or how to send an NDI notification. The government has arbitrarily ignored or enforced this section of DSHEA, doing as it liked, without spelling out the rules.

Why does this matter? Because when you hear New Dietary Ingredient (NDI), substitute “New Supplement” in your mind. What we are dealing with here is whether the supplement industry is allowed to innovate and create new supplements—and if so, under what rules.

Heavy Coffee Consumption Linked to Better Hep C Treatment Response

Patients with advanced hepatitis C virus–related liver disease who drank three or more cups of coffee per day were three times more likely to respond to therapy with peginterferon alfa-2a plus ribavirin at four time points than were patients who didn’t drink coffee, Neal David Freedman, Ph.D., and his colleagues reported in the June issue of Gastroenterology.

Syndicate content